According to the press release, Cellectis, a biotechnology company listed on Euronext Growth and Nasdaq, will present significant clinical data for its product lasmé-cel during the webinar. Designed for patients with relapsed or refractory B-cell acute lymphoblastic leukemia, this product was discussed during the R&D Day on October 16, 2025. The company also plans to discuss the design of the pivotal Phase 2 clinical trial, the registration pathway, and the commercial potential of lasmé-cel, estimated to reach up to about $700 million in annual sales at peak.
Future Directions for éti-cel Program
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Cellectis will also discuss the next steps for the éti-cel program, targeting patients with relapsed or refractory non-Hodgkin lymphoma. The webinar will include a review of the company's strategic collaborations and recent advancements in genome editing. Cellectis' executives will answer questions from the audience, which were previously submitted via email.
Webinar Details
The webinar is scheduled for December 4, 2025, at 2:00 PM Paris time, and will be hosted by Dr. André Choulika, Dr. Laurent Poirot, and Arthur Stril. Participants can register via a link provided in the press release, and a recording of the event will be available later on Cellectis' website.
SectorSanté · Biotechnologies · Vaccins et laboratoires de recherche›Biotechnologie
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.
